| scholarly article | Q13442814 |
| P50 | author | John B. Porter | Q37829427 |
| P2093 | author name string | Bart J Biemond | |
| Eldad A Hod | |||
| Gary M Brittenham | |||
| Dorine W Swinkels | |||
| Renzo Galanello | |||
| Z Ioav Cabantchik | |||
| Lisa N van der Vorm | |||
| Robert C Hider | |||
| Jan C M Hendriks | |||
| Mirian C H Janssen | |||
| Patricia J Evans | |||
| Raffaella Origa | |||
| Marius A MacKenzie | |||
| Louise de Swart | |||
| Yael Furman | |||
| Boguslaw Wojczyk | |||
| Vera E J M Mattijssen | |||
| P2860 | cites work | Quantification of non-transferrin-bound iron in the presence of unsaturated transferrin | Q78198074 |
| Redox active plasma iron in C282Y/C282Y hemochromatosis | Q81321025 | ||
| Non-transferrin bound iron in Thalassemia: differential detection of redox active forms in children and older patients | Q82719965 | ||
| Improved quantification for non-transferrin-bound iron measurement using high-performance liquid chromatography by reducing iron contamination | Q84483896 | ||
| Potential problems in the determination of serum non-transferrin-bound iron using nitrilotriacetic acid and ultrafiltration | Q86693439 | ||
| Serum ferritin: Past, present and future | Q24626621 | ||
| Influence of non-enzymatic post-translation modifications on the ability of human serum albumin to bind iron. Implications for non-transferrin-bound iron speciation | Q28247753 | ||
| Desferrioxamine-chelatable iron, a component of serum non-transferrin-bound iron, used for assessing chelation therapy | Q31828423 | ||
| Iron and citric acid: a fuzzy chemistry of ubiquitous biological relevance | Q33930116 | ||
| Nature of nontransferrin-bound iron | Q34557036 | ||
| Transfusion of human volunteers with older, stored red blood cells produces extravascular hemolysis and circulating non-transferrin-bound iron. | Q35623668 | ||
| Relative response of patients with myelodysplastic syndromes and other transfusion-dependent anaemias to deferasirox (ICL670): a 1-yr prospective study | Q36499650 | ||
| Monitoring the efficiency of iron chelation therapy: the potential of nontransferrin-bound iron. | Q37780291 | ||
| Non-transferrin bound iron: a key role in iron overload and iron toxicity | Q37920197 | ||
| Labile iron in cells and body fluids: physiology, pathology, and pharmacology | Q38198634 | ||
| Guidelines for quantifying iron overload | Q38361653 | ||
| A novel method for non-transferrin-bound iron quantification by chelatable fluorescent beads based on flow cytometry | Q39198457 | ||
| A decisional algorithm to start iron chelation in patients with beta thalassemia | Q42000881 | ||
| Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity | Q42024944 | ||
| Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded beta-thalassemia/HbE patients treated with an oral chelator | Q42461969 | ||
| Relationship between labile plasma iron, liver iron concentration and cardiac response in a deferasirox monotherapy trial | Q42783336 | ||
| Pathogenesis and management of iron toxicity in thalassemia | Q42936413 | ||
| Deferasirox in iron-overloaded patients with transfusion-dependent myelodysplastic syndromes: Results from the large 1-year EPIC study | Q43069758 | ||
| Iron(III) citrate speciation in aqueous solution. | Q43265936 | ||
| Daily labile plasma iron as an indicator of chelator activity in Thalassaemia major patients | Q43274578 | ||
| Labile plasma iron in iron overload: redox activity and susceptibility to chelation | Q44477026 | ||
| Survival and complications in patients with thalassemia major treated with transfusion and deferoxamine | Q45101211 | ||
| Comparison of bleomycin-detectable iron and labile plasma iron assays | Q45165095 | ||
| Results of an international round robin for the quantification of serum non-transferrin-bound iron: Need for defining standardization and a clinically relevant isoform | Q46502128 | ||
| Nature of non-transferrin-bound iron: studies on iron citrate complexes and thalassemic sera | Q46973687 | ||
| Nontransferrin-bound iron in transfused patients with sickle cell disease. | Q53262911 | ||
| Levels of non-transferrin-bound iron as an index of iron overload in patients with thalassaemia intermedia | Q57998334 | ||
| High nontransferrin bound iron levels and heart disease in thalassemia major | Q62018235 | ||
| A direct method for quantification of non-transferrin-bound iron | Q68838629 | ||
| Non-transferrin-bound iron in plasma or serum from patients with idiopathic hemochromatosis. Characterization by high performance liquid chromatography and nuclear magnetic resonance spectroscopy | Q69057573 | ||
| Measurement of iron and copper in biological systems: bleomycin and copper-phenanthroline assays | Q71630063 | ||
| An improved simple colorimetric method for quantitation of non-transferrin-bound iron in serum | Q72293357 | ||
| Non-transferrin-bound iron, iron-related oxidative stress and lipid peroxidation in beta-thalassemia intermedia | Q73252052 | ||
| The assessment of serum nontransferrin-bound iron in chelation therapy and iron supplementation | Q73708500 | ||
| P433 | issue | 1 | |
| P304 | page(s) | 38-45 | |
| P577 | publication date | 2015-09-18 | |
| P1433 | published in | Haematologica | Q5638209 |
| P1476 | title | Second international round robin for the quantification of serum non-transferrin-bound iron and labile plasma iron in patients with iron-overload disorders | |
| P478 | volume | 101 |
| Q38801048 | Catalytic iron and acute kidney injury. |
| Q37416334 | Clinical and methodological factors affecting non-transferrin-bound iron values using a novel fluorescent bead assay |
| Q97545523 | Controversies on the Consequences of Iron Overload and Chelation in MDS |
| Q50034053 | Determination of Non-Transferrin Bound Iron, Transferrin Bound Iron, Drug Bound Iron and Total Iron in Serum in a Rats after IV Administration of Sodium Ferric Gluconate Complex by Simple Ultrafiltration Inductively Coupled Plasma Mass Spectrometric |
| Q47198405 | Effect of red blood cell storage time on markers of hemolysis and inflammation in transfused very low birth weight infants |
| Q39179372 | How we manage iron overload in sickle cell patients |
| Q40171404 | Impact of non-transferrin-bound iron (NTBI) in comparison to serum ferritin on outcome after allogeneic stem cell transplantation (ASCT). |
| Q92571414 | Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes |
| Q94543881 | Iron metabolism imbalance at the time of listing increases overall and infectious mortality after liver transplantation |
| Q47230788 | Iron reduction response and demographic differences between diabetics and non-diabetics with cardiovascular disease entered into a controlled clinical trial |
| Q64098992 | Iron uptake by ZIP8 and ZIP14 in human proximal tubular epithelial cells |
| Q46264493 | Labile plasma iron levels predict survival in patients with lower-risk Myelodysplastic syndromes. |
| Q47603695 | Laboratory methodologies for indicators of iron status: strengths, limitations, and analytical challenges |
| Q48334711 | Linking iron-deficiency with allergy: role of molecular allergens and the microbiome |
| Q90652303 | Low-molecular-mass iron complexes in blood plasma of iron-deficient pigs do not originate directly from nutrient iron |
| Q88888632 | Low-molecular-mass iron in healthy blood plasma is not predominately ferric citrate |
| Q38836181 | Management of iron overload in hemoglobinopathies: what is the appropriate target iron level? |
| Q92157114 | Pharmacokinetics of ferric bepectate-a new intravenous iron drug for treating iron deficiency |
| Q37545024 | Prolonged red cell storage before transfusion increases extravascular hemolysis |
| Q36830103 | Safety, pharmacokinetics and pharmacodynamics of the anti-hepcidin Spiegelmer lexaptepid pegol in healthy subjects |
| Q47140948 | Should every Patient with MDS get Iron Chelation – Probably Yes. |
| Q51017552 | Stored blood: how old is too old? |
| Q90288843 | The multifaceted role of iron in renal health and disease |
| Q90470319 | Transfusional iron overload and intravenous iron infusions modify the mouse gut microbiota similarly to dietary iron |
Search more.